Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy

Haematologica. 2016 Apr;101(4):e153-6. doi: 10.3324/haematol.2015.138016. Epub 2016 Jan 14.
No abstract available

Keywords: HSCT; IL-15-activated; cytokine-induced killer cells; efficacy; immunological control; relapse.

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Cytokine-Induced Killer Cells / cytology
  • Cytokine-Induced Killer Cells / drug effects
  • Cytokine-Induced Killer Cells / immunology
  • Cytokine-Induced Killer Cells / transplantation*
  • Female
  • Graft vs Host Disease / diagnosis
  • Graft vs Host Disease / immunology
  • Graft vs Host Disease / pathology
  • Haplotypes
  • Hematopoietic Stem Cell Transplantation*
  • Histocompatibility Testing
  • Humans
  • Infant
  • Interleukin-15 / pharmacology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Leukemia, Myeloid, Acute / immunology
  • Leukemia, Myeloid, Acute / pathology
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy*
  • Recurrence
  • Remission Induction
  • Tissue Donors
  • Transplantation, Homologous

Substances

  • Interleukin-15